We identified B cell maturation antigen (BCMA) as a potential therapeutic target in 778 newly diagnosed and relapsed myeloma patients. We constructed an IgG-based BCMA-T cell bispecific antibody (EM801) and showed that it increased CD3+ T cell/myeloma cell crosslinking, followed by CD4+/CD8+ T cell activation, and secretion of interferon-γ, granzyme B, and perforin. This effect is CD4 and CD8 T cell mediated. EM801 induced, at nanomolar concentrations, myeloma cell death by autologous T cells in 34 of 43 bone marrow aspirates, including those from high-risk patients and patients after multiple lines of treatment, tumor regression in six of nine mice in a myeloma xenograft model, and depletion of BCMA+ cells in cynomolgus monkeys. Pharmacoki...
We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multi...
Multiple myeloma is a prevalent and incurable disease, despite the development of new and effective ...
B-cell maturation antigen (BCMA), highly expressed on malignant plasma cells in human multiple myelo...
We identified B cell maturation antigen (BCMA) as a potential therapeutic target in 778 newly diagno...
B-cell maturation antigen (BCMA)-targeting bispecific antibodies and bispecific T-cell engagers (BiT...
BCMA antigen is overexpressed in multiple myeloma cells and has been shown to be a promising target ...
B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its hi...
Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substa...
Despite the discoveries of numerous agents including next generation proteasome inhibitors, immunomo...
Purpose: Multiple myeloma (MM) patients with disease refractory to all available drugs have a poor o...
CD38 and B-cell maturation antigens (BCMAs) are prevalently expressed on neoplastic plasma cells in ...
Multiple myeloma (MM) patients eventually develop multi-drug-resistant disease with poor survival. H...
The cell-surface protein B cell maturation antigen (BCMA, CD269) has emerged as a promising target f...
International audienceB-cell maturation antigen (BCMA) is an attractive therapeutic target highly ex...
Background: B-cell maturation antigen (BCMA) is a cell-surface receptor of the tumour necrosis supe...
We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multi...
Multiple myeloma is a prevalent and incurable disease, despite the development of new and effective ...
B-cell maturation antigen (BCMA), highly expressed on malignant plasma cells in human multiple myelo...
We identified B cell maturation antigen (BCMA) as a potential therapeutic target in 778 newly diagno...
B-cell maturation antigen (BCMA)-targeting bispecific antibodies and bispecific T-cell engagers (BiT...
BCMA antigen is overexpressed in multiple myeloma cells and has been shown to be a promising target ...
B cell maturation antigen (BCMA) is a novel treatment target for multiple myeloma (MM) due to its hi...
Despite considerable advances in the treatment of multiple myeloma (MM) in the last decade, a substa...
Despite the discoveries of numerous agents including next generation proteasome inhibitors, immunomo...
Purpose: Multiple myeloma (MM) patients with disease refractory to all available drugs have a poor o...
CD38 and B-cell maturation antigens (BCMAs) are prevalently expressed on neoplastic plasma cells in ...
Multiple myeloma (MM) patients eventually develop multi-drug-resistant disease with poor survival. H...
The cell-surface protein B cell maturation antigen (BCMA, CD269) has emerged as a promising target f...
International audienceB-cell maturation antigen (BCMA) is an attractive therapeutic target highly ex...
Background: B-cell maturation antigen (BCMA) is a cell-surface receptor of the tumour necrosis supe...
We here defined the impacts of γ-secretase inhibitors (GSIs) on T-cell-dependent BCMA-specific multi...
Multiple myeloma is a prevalent and incurable disease, despite the development of new and effective ...
B-cell maturation antigen (BCMA), highly expressed on malignant plasma cells in human multiple myelo...